Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 9 | 10 |
| 1995 | 3 | 13 | 16 |
| 1996 | 3 | 22 | 25 |
| 1997 | 4 | 17 | 21 |
| 1998 | 2 | 19 | 21 |
| 1999 | 3 | 17 | 20 |
| 2000 | 6 | 25 | 31 |
| 2001 | 2 | 18 | 20 |
| 2002 | 2 | 38 | 40 |
| 2003 | 9 | 24 | 33 |
| 2004 | 5 | 20 | 25 |
| 2005 | 4 | 23 | 27 |
| 2006 | 2 | 16 | 18 |
| 2007 | 3 | 15 | 18 |
| 2008 | 3 | 12 | 15 |
| 2009 | 6 | 8 | 14 |
| 2010 | 1 | 13 | 14 |
| 2011 | 5 | 10 | 15 |
| 2012 | 3 | 9 | 12 |
| 2013 | 4 | 5 | 9 |
| 2014 | 3 | 3 | 6 |
| 2015 | 1 | 7 | 8 |
| 2016 | 2 | 6 | 8 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 5 | 7 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 2 | 3 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
-
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024 Jun; 26(6):2209-2228.
-
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23; 403(10432):1141-1152.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials. Pharmaceut Med. 2024 Jan; 38(1):63-73.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01; 12(2):168-183.
-
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 06 10; 40(17):1939-1948.